Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including annual and quarterly reports, current reports, and proxy materials. As an artificial intelligence-powered precision cardiovascular medicine company listed on The Nasdaq Stock Market LLC, Cardio Diagnostics uses these filings to report on its operations, governance, capital structure, and key corporate events.
Through documents such as Form 10-K and Form 10-Q, investors can review detailed information about the company’s business, including its focus on AI-driven Integrated Genetic-Epigenetic technology for cardiovascular disease, the development and commercialization of its Epi+Gen CHD and PrecisionCHD tests, and risk factors relevant to its operations. Form 8-K current reports, such as the filing describing the company’s regaining compliance with Nasdaq’s minimum bid price requirement, provide timely updates on material events, corporate actions, and listing status.
Proxy statements filed on Schedule 14A offer insight into Cardio Diagnostics’ corporate governance, including the election of directors, proposals related to future share issuances under Nasdaq rules, and the ratification of its independent registered public accounting firm. These documents also describe how stockholders can participate in virtual annual meetings and vote on key matters.
On Stock Titan, Cardio Diagnostics filings are updated in near real time from the SEC’s EDGAR system and are accompanied by AI-powered summaries that highlight important sections and explain complex disclosures in clear language. Users can quickly locate information about capital markets activity, such as approvals for potential future share issuances, and monitor governance decisions documented in proxy materials. For investors analyzing CDIO, this page serves as a centralized resource for reviewing the company’s regulatory history and understanding how its precision cardiovascular medicine strategy is reflected in formal SEC reporting.
Cardio Diagnostics Holdings is hosting an investor call to review its current status, recent developments, and strategic priorities, supported by an investor presentation. The company focuses on precision cardiovascular medicine using epigenetics and artificial intelligence to prevent and detect heart disease earlier and more accurately.
The presentation highlights two AI-powered blood tests: Epi+Gen CHD, which estimates three-year coronary heart disease risk and has an estimated U.S. market of about $125 billion with 146 million eligible Americans, and PrecisionCHD, a diagnostic aid with an estimated $51 billion U.S. market and 60 million eligible Americans, both tied to a final CMS payment rate of $854 per test. Management emphasizes growing clinical validation, cost-effectiveness studies, and international partnerships, including a recently launched internal CLIA lab that has reduced initial lab cost of goods by roughly 30% and targets test turnaround times of about 7–10 business days.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung reported receiving a grant of stock options. On 12/31/2025, he was awarded options to buy 2,306 shares of common stock at an exercise price of $2.71 per share. After this grant, he beneficially owns a total of 6,308 stock options directly. This filing records the equity compensation awarded to a board member and does not involve any sale of shares.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts reported a stock option grant. On December 31, 2025, she was awarded 2,306 stock options with a right to buy common stock at an exercise price of $2.71 per share. After this grant, she beneficially owns 6,308 derivative securities in the form of stock options, held with direct ownership.
Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award. On 12/31/2025, he was granted 2,306 stock options (right to buy common stock) with a conversion or exercise price of $2.71 per share. After this grant, he beneficially owns 7,259 derivative securities in the form of stock options, held in direct ownership. The filing was made on Form 4 for a single reporting person, reflecting an option grant coded as an acquisition.
Cardio Diagnostics (CDIO) filed its Q3 2025 10-Q, showing minimal sales and ongoing investment in operations. Revenue was $2,855 for the quarter and $11,270 year-to-date. Operating expenses were $1,714,452 in Q3 and $5,032,126 year-to-date. The company reported a net loss of $1,714,536 for Q3 and $5,032,799 for the first nine months.
Cash stood at $6,355,218 as of September 30, 2025, with net cash used in operating activities of $4,364,984 year-to-date. The share count increased as the company raised capital: 1,766,607 shares were outstanding at quarter-end and 1,826,051 as of November 12, 2025. The company executed a 1-for-30 reverse stock split effective May 12, 2025 to maintain Nasdaq compliance. Through its at-the-market program, the company has sold shares for net proceeds of $15,061,270 as of November 12, 2025, including a post-quarter sale of 59,444 shares for $269,813.
Cardio Diagnostics Holdings, Inc. reported results from its annual meeting held on
Stockholders approved the Share Issuance Proposal authorizing future issuances of common stock and/or convertible or exercisable securities equal to 20% or more of outstanding common stock in one or more non‑public transactions, within the parameters described in the proxy statement. Votes were 283,304 for, 166,492 against, and 15,183 abstaining, with 462,547 broker non‑votes.
They also ratified Prager Metis CPA’s LLC as independent auditor for the year ending December 31, 2025, with 813,401 for, 64,820 against, and 49,305 abstentions.
Peter Fung, a director of Cardio Diagnostics Holdings, Inc. (CDIO), reported a non-derivative change tied to stock options dated 09/30/2025. The filing shows 1,559 stock options were acquired with an exercise price of $4.01, exercisable immediately and expiring on 09/30/2035. After the transaction, Mr. Fung beneficially owned 4,002 shares of common stock on a direct basis.
Director Wendy J. Betts reported acquiring 1,559 stock options of Cardio Diagnostics Holdings, Inc. (CDIO) on 09/30/2025. The options have an exercise price of $4.01, are exercisable immediately (09/30/2025) and expire on 09/30/2035. The filing shows these options cover 1,559 underlying shares, and following the reported transaction Ms. Betts beneficially owns 4,002 shares of common stock. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. The report is a Section 16 disclosure of insider changes in beneficial ownership and contains no additional financial results or contractual terms beyond the option details.
James Intrater, a director of Cardio Diagnostics Holdings, Inc. (CDIO), exercised 1,559 stock options on 09/30/2025 at an exercise price of $4.01 per share, converting those options into 1,559 shares of common stock. After the transaction he directly beneficially owns 4,953 shares. The Form 4 reports this routine equity award exercise and shows the resulting direct ownership level.
Paul Burton, a director of Cardio Diagnostics Holdings, Inc. (CDIO), exercised stock options on 09/30/2025 to acquire 1,559 shares at an exercise price of $4.01 per share. The options are exercisable immediately and expire on 09/30/2035. Following the reported transaction, Mr. Burton beneficially owns 4,953 shares of common stock. The Form 4 was filed via signature by Elisa Luqman as attorney-in-fact on 10/03/2025. The filing identifies the reporting person as a director and shows the ownership form as direct.